New Treatments for Hepatobiliary Cancer

Dear Colleagues,

Hepatobiliary cancers are among the most frequently occurring types of tumor worldwide. After years of unsatisfactory results, combinations of treatments ranging from traditional chemotherapy regimens to immunotherapy have finally changed the approach to advanced disease control, providing better outcomes in the advanced setting, even if locoregional control still remains the primary aim of treatment. This Issue focalizes its attention on new treatments for hepatobiliary cancers in a broader meaning, encompassing issues such the literal proposition of new drugs or treatments; the integration of a current treatment to either locoregional procedures or systemic treatments; and the personalization and optimization of treatments to improve the results of therapies. Therefore, this Issue embraces a wide range of interests: the identification of specific subsets of patients to personalize treatment, the proposal of new locoregional treatments or protocols, the integration of different treatments in any possible setting, the analysis of data from new drugs including immunotherapics, the best indications for already available drugs, the possible improvements in sequences of drugs, and the usefulness of any possible treatment in efforts to enhance responses and tolerance to treatment.

Dr. Girolamo Ranieri
Dr. Davide Quaresmini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.